Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Dermatopathol ; 45(8): 519-531, 2023 Aug 01.
Article in English | MEDLINE | ID: mdl-37462204

ABSTRACT

ABSTRACT: Immunodeficiency-associated lymphoproliferative disorders (IA-LPDs) constitute a diverse range of conditions including posttransplant lymphoproliferative disorders, other iatrogenic IA-LPDs, and lymphoproliferative disorders associated with an underlying primary immune disorder or HIV infection. IA-LPDs are clinically and pathologically heterogeneous, and there is a lack of standardization of diagnostic terminology. They can represent a potential serious diagnostic pitfall because the histological features of clinically indolent proliferations may mimic those of high-grade lymphoma. However, correct identification of these entities is essential given that complete remission may occur upon reversal of the underlying cause of immunosuppression without the need for systemic therapy. IA-LPDs presenting in the skin are rare but well documented. One form of iatrogenic IA-LPD, methotrexate-associated lymphoproliferative disorder (MTX-LPD), can present with cutaneous nodules, plaques, or ulcers. Predominantly, MTX-LPD develops in the context of long-term treatment of autoimmune conditions, such as rheumatoid arthritis, dermatomyositis, and Sjögren syndrome, and may be associated with underlying Epstein-Barr virus (EBV) infection. We present 4 cases of cutaneous EBV-positive B-cell MTX-LPD and describe their clinical and morphological findings. Comparison of our histological findings to the diagnostic criteria for EBV-positive mucocutaneous ulcer (EBVMCU) revealed significant overlap, highlighting the intersection between MTX-LPD and EBVMCU. Withdrawal of methotrexate resulted in healing of all lesions at a mean time of 2 months. In summary, close clinicopathological correlation is vital to identify MTX-LPD presenting as cutaneous EBVMCU given that the initial treatment strategy is that of withdrawal of methotrexate without the need for immediate systemic therapy.


Subject(s)
Epstein-Barr Virus Infections , HIV Infections , Immunologic Deficiency Syndromes , Lymphoma, B-Cell , Lymphoproliferative Disorders , Precancerous Conditions , Humans , Methotrexate/adverse effects , Epstein-Barr Virus Infections/diagnosis , Epstein-Barr Virus Infections/pathology , Herpesvirus 4, Human , Ulcer/pathology , HIV Infections/complications , Lymphoma, B-Cell/drug therapy , Lymphoproliferative Disorders/chemically induced , Lymphoproliferative Disorders/diagnosis , Precancerous Conditions/drug therapy , Iatrogenic Disease
2.
Clin Exp Dermatol ; 47(8): 1617-1621, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35661395

ABSTRACT

A woman who had undergone haematopoietic stem cell transplantation presented with cutaneous features suggestive of graft-versus-host disease. Histopathological examination revealed a diffuse dermal infiltration of atypical monomorphic cells with a high proliferative index. Immunohistochemistry revealed positivity for monocytic markers, but negativity for T-cell markers.


Subject(s)
Exanthema , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Prurigo , Female , Graft vs Host Disease/diagnosis , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Pruritus
3.
World J Surg Oncol ; 7: 55, 2009 Jun 23.
Article in English | MEDLINE | ID: mdl-19549298

ABSTRACT

BACKGROUND: Hepatic embryonal sarcoma (HES) is a rare but aggressive primary tumor of the liver occurring most frequently in childhood. CASE PRESENTATION: We report a case of a 52 year old woman having previously undergone treatment for ovarian serous papillary carcinoma who subsequently presented with a large solitary mass in the liver. Initially this was presumed to be metastasis from the ovarian primary however, on further examination it was shown to be a primary hepatic embryonal sarcoma. CONCLUSION: Primary liver tumors should be considered in differential diagnoses in patients with ovarian cancer who subsequently present with liver tumors. This is particularly important when there is no direct evidence of recurrence of ovarian cancer.


Subject(s)
Carcinoma, Papillary/pathology , Cystadenocarcinoma, Serous/pathology , Liver Neoplasms/pathology , Neoplasms, Germ Cell and Embryonal/pathology , Neoplasms, Second Primary/pathology , Ovarian Neoplasms/pathology , Sarcoma/pathology , CA-125 Antigen/blood , Female , Humans , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Middle Aged , Neoplasms, Germ Cell and Embryonal/therapy , Sarcoma/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...